TCL Archive DCT Board Committee Drawing Up Plans On How To Spend Biological Response Modifiers Money August 31, 1979
TCL Archive Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable January 31, 2003
TCL Archive Special Report on the American Legacy Foundation: As Legacy seeks new funding, critics fear symbiosis with Big Tobacco. Legacy, NCI, C-Change relationship could open door to industry influence, lawyer says. October 29, 2004